Introduction: Potential disparities in the diagnosis, treatment, and survival of patients with lung cancer with and without disabilities have rarely been investigated.
Introduction
Lung cancer is the leading cause of cancer death worldwide and in the Republic of Korea. 1, 2 Although lung cancer was once perceived as a deadly disease, it is now understood that early detection and adequate treatment can reduce the mortality and morbidity burden from it.
Socially disadvantaged populations, such as low-income people or ethnic minorities, often have their cancer diagnosed at a later stage, receive less intensive or inappropriate therapy, and experience shorter survival than do people with greater social advantages. 3 For, people with disabilities. the associations are not clear or consistent among disability types and different cancers. [4] [5] [6] Few studies have been conducted on the potential disparities in the diagnosis and treatment of lung cancer with regard to disability, mainly owing to lack of information on disabilities in data sources. 5 Notably, a U.S. study using the Surveillance, Epidemiology, and End ResultsMedicare/Social Security Disability Insurance (SSDI) databases examined differences in the stage at diagnosis and survival in patients younger than 65 years 5 and disparities in treatment and survival in patients with stage I disease. 4 The study showed that although their disease was diagnosed at an earlier stage, people with disabilities were less likely to undergo a surgical procedure after a diagnosis of stage I cancer. 5 They had significantly higher cancer mortality, but the mortality difference disappeared after accounting for treatment differences. 4 Although this was the largest study of its kind to date, it had the following limitations: (1) Medicare/SSDI status is not an accurate indicator of disability (e.g., people with disabilities who work are not eligible for Medicare/SSDI); (2) only people younger than 65 years were studied, which limited the representativeness of the sample in terms of age; (3) differences in health care access exist between the two groups (a significant portion of people without disabilities are underinsured or uninsured in contrast to the group receiving Medicare/SSDI); (4) analyses of treatment were limited to stage I cancer, and chemotherapy information was not available; (5) the study included only five broad conditions (i.e., visual and hearing disabilities were not included); and (6) information on severity of disability was also not available.
In the Republic of Korea, all people are covered by universal health insurance, and the copay for cancer work-up and treatment is only 5%, with a maximum copay for low-income people of only approximately $1000 as of 2016. In addition, the Republic of Korea has a national disability registration system, which defines disability types and severity according to preset criteria and medical diagnosis. These are optimal conditions for examining disparities in lung cancer care related to disabilities. Using the linked administrative database in the Republic of Korea, we investigated the potential disparities in the diagnosis, treatment, and survival of patients with a diagnosis of lung cancer between people with and without disabilities.
Methods

Study Setting and Data Source
Korean National Health Service. The Korean National Health Service (KNHS) provides public health insurance for virtually all Korean people except for Medicaid beneficiaries in the lowest income bracket (3% of the population). Medical service providers are reimbursed for their services mainly on a fee-for-service basis. Therefore, the KNHS contains all the data necessary for reimbursement, including disease codes; costs incurred for inpatient and outpatient services; and a detailed list of diagnostic tests, procedures and other medical treatments, and prescription medications. It also includes demographic data on the enrollees, such as age, sex, residential area, and income status (premium level is determined by income). The KNHS database has been widely used in various epidemiological and health policy studies. 7, 8 Details of the database profile are described elsewhere. 9, 10 The KNHS provides a free biennial health screening program for all people older than 40 years and all employees regardless of age. 7 This program aims to detect cardiovascular risk factors and comprises a questionnaire about medical history and health behavior, anthropometric measurements, and laboratory tests.
Disability Registration System in the Republic of Korea. In 1988, a national registration system was established for people with disabilities, mainly for the provision of welfare benefits, which are determined by the type and severity of disability. There are 15 legally defined types of disability: limb, brain, visual, auditory, linguistic, facial, kidney, heart, liver, respiratory system, ostomy, epilepsy, intellectual, autistic, and mental disabilities. Disability registration requires submission of validated documentation to a local National Pension Service office, including appraised results of disability diagnosis by a specialist physician in the corresponding field (Supplementary Table 1 ). The severity of the disability is determined by the specialist physician according to government guidelines and predefined criteria based on the functional losses and clinical impairment presented by the patient, with severity classified into six levels (Supplementary Table 2) . [11] [12] [13] For our analyses, disability types were reclassified as (1) physical impairment (limb disability), (2) communication impairment (visual, auditory, or linguistic disability), (3) mental impairment (brain, intellectual, autistic, or mental disability), (4) cardiopulmonary impairment (heart or lung disability), and (5) other impairment. We also dichotomized levels of severity into severe (grades 1-3) and mild (grades 4-6), according to government criteria.
Cancer Registration System in the Republic of Korea. The Korean Central Cancer Registry is a government-sponsored, nationwide cancer registry that has been active since 1980. The available data include sex; age at diagnosis; date of diagnosis; cancer site; and Surveillance, Epidemiology, and End Results summary stage (in situ and local, regional, distant, and unknown).
Study Subjects
First, we linked the KNHS database with national disability registration data and selected three age-and sex-matched controls for each subject with any registered disability in 2009-2013. Second, the Korean Central Cancer Registry provided cancer registration data for all subjects in the KNHS disability study data set for data linkage.
The study population included all subjects in whom lung cancer was diagnosed (International Classification of Diseases code C34) from January 1, 2009, to December 31, 2013 (N ¼ 62,832). Control subjects with lung cancer were assigned an index date corresponding to the date of the lung cancer diagnosis of their matched patients with lung cancer. We excluded patients who (1) were younger than 19 years at the time of diagnosis or index date (n ¼ 4), (2) had a history of other cancers (except for thyroid cancer 14, 15 ) before diagnosis of their lung cancer (n ¼ 5211), or (3) had missing data (n ¼ 217) (Fig. 1) .
The final sample consisted of 57,400 subjects with a lung cancer diagnosis, of whom 13,591 had a disability and 43,809 did not (control subjects). Therefore, the case-to-control ratio was generally well maintained (case-to-control ratio 1:3.22). Finally, we linked our data set to vital statistics.
To investigate the survival of patients with lung cancer who had undergone a surgical procedure with curative intent, we designated a surgery subset by restricting the study population to those with localized disease who had undergone a surgical procedure. People with heart and lung disabilities were further excluded as those disabilities may limit the option of surgery for treatment. Institutional review board approval was obtained from Chungbuk National University (institutional review board approval No. CBNU-201708-BM-501-01).
Statistical Analysis
Descriptive statistics were summarized for presence or absence of disabilities and for people with disabilities according to the five predefined categories and severity 
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Lung Cancer among People with Disabilities of the disability. Cancer stage at diagnosis and treatment received were also analyzed and tested by chi-square test. Surgical procedures were categorized as wedge resection, segmentectomy, lobectomy, and pneumonectomy according to the extent of surgery. Chemotherapy and radiation therapy were not further categorized owing to the complexity of the regimens. Relative probabilities of receiving a specific treatment (i.e., surgery, radiotherapy, and chemotherapy) were calculated by logistic regression analyses and adjusted for age, sex, Charlson comorbidity index, 16 income, place of residence, and cancer stage. Cox proportional hazards regression analysis was used to determine the hazard ratios (HRs) for overall and lung cancer-specific mortality for people with disabilities versus for people without disabilities. Survival time was calculated from the lung cancer diagnosis or index date until the date of death, censor date (outmigration or death from other causes for lung cancer-specific mortality), or December 31, 2015, whichever came first. Smoking and body mass index were further taken into account for those who participated in the screening program. With the surgery subset, we also ran separate Cox proportional hazards regression analyses.
All the analyses were performed by using the SAS statistical software (version 9.4; SAS Institute, Inc., Cary, NC). p Values less than 0.05 were considered statistically significant.
Results
Study Participants
Patients with lung cancer and disabilities were slightly younger than the control subjects (68.9 versus 69.7 years) and slightly less likely to be female (21.7% versus 23.9%). They had more comorbidities and a higher mean Charlson comorbidity index score (2.4 versus 1.8) and were more likely to have a lower income and live in a rural area (Table 1 and Supplementary  Table 3 ).
Stage at Diagnosis by Disability
There was no significant difference in stage of diagnosis between patients with lung cancer with and without disabilities. However, unknown stage was more common in people with severe disabilities (13.1% versus 10.3%), especially those with communication (14.2%) or brain/mental disability (15.7%). By contrast, the lung cancer of people with cardiopulmonary impairment tended to be diagnosed in an earlier stage (Table 2) .
Treatment Received according to Disability
People with disabilities were less likely to undergo a surgical procedure (19.8% versus 21.9%), chemotherapy (42.3% versus 46.1%), or radiotherapy (26.4% versus 27.6%) ( Table 3 Table 3 ). Treatment differences analyzed according to stage at diagnosis are displayed in Supplementary Table 4 .
Survival according to Disability
During follow-up, 78.7% of subjects (45,191 of 57,400) died. Patients with lung cancer and disabilities had a slightly higher overall mortality risk than people with no disability (adjusted hazard ratio [aHR] ¼ 1.08, 95% CI: 1.06-1.11). This difference was especially marked in the severe disability group (aHR ¼ 1.20, 95% CI: 1.16-1.24), whereas overall mortality was only slightly higher in the mild disability group (aHR ¼ 1.03, 95% CI: 1.01-1.06). In the high-severity group, risk was markedly higher in the group with brain/mental impairment (aHR ¼ 1.37, 95% CI: 1.28-1.45) and slightly higher in the groups with physical impairment (aHR ¼ 1.16, 95% CI: 1.10-1.23) and communication impairment (aHR ¼ 1.20, 95% CI: 1.07-1.34). As 94% of all deaths were lung cancer deaths, the estimates were similar to those for lung cancer mortality (Table 4) . Similar but slightly attenuated trends were observed when the analysis was limited to screening program participants, with further adjustment for smoking and body mass index (Supplementary Table 5 ).
Survival according to Disability in Patients with Localized Disease Who Underwent a Curative Surgical Procedure
Patients with lung cancer and disabilities had higher overall mortality than did people with no disability (aHR ¼ 1.29, 95% CI: 1.12-1.47). This difference was especially marked with in those with a severe disability (aHR ¼ 1.79, 95% CI: 1.42-2.24) but was not significant in those with a mild disability (aHR ¼ 1.16, 95% CI: 0.99-1.35). In the high-severity group, risk was significantly higher in the groups with physical (aHR 2.08, 95% CI: 1.49-2.90) or brain/mental (aHR ¼ 1.57, 95% CI: 1.02-2.40) impairment. Again, the estimates were consistent with those for lung cancer mortality (see Table 5 ) and those when the analysis was limited to screening program participants (Supplementary Table 6 ).
Discussion
To our knowledge, this is the first study to comprehensively analyze potential disparity in the whole spectrum of lung cancer care related to disabilities, including the stage at diagnosis, treatment received, and overall and cancer-specific mortality. Strengths include the large number of participants constituting a representative sample, inclusion of a wide range of disability types, and accurate disability diagnoses.
We found that lung cancer was not diagnosed later in patients with a disability than in those without a disability. The earlier stage at diagnosis in people with cardiopulmonary impairment suggests opportunistic detection of lung cancer during routine follow-up (e.g., chest radiography or computed tomography) related to their disabilities. 7 During the study period (2009-2013), a lung cancer screening program was not available in the Republic of Korea. 18 Although people with disabilities often show lower participation in cancer screening programs 19, 20 and are susceptible to late diagnosis, the lack of a difference in the stage at diagnosis in our study suggests that this screening effect did not exist for lung cancer.
Cancer stages for people with severe disabilities were more likely to be left unknown, especially when they have communication or brain/mental disability. Unknown stage means that the patients did not receive proper staging tests to establish an appropriate treatment plan, and it suggests that they gave up subsequent treatment. As a disability itself is not a contraindication for cancer treatment, this might reflect the ableism of the patients, family, or health care professionals, which is to say the attitudes in society that devalue and limit the potential of people with disabilities. 21 Moreover, people with disabilities were less likely to receive all treatment modalities and were more likely to get no treatment at all. Again, our finding suggests that people with disabilities are either discouraged from obtaining treatment by health care professionals or that they themselves give up the treatment by their own decision. 21 It is likely that they might underestimate the treatment benefit or overestimate the chance of treatment-related complications for people with disabilities. In addition, practical concerns may limit treatment choices for some people with a disability (e.g., giving up daily radiotherapy owing to transportation problems). 5 Of note, the degree of disparity in radiotherapy was less than those for surgery or chemotherapy (aOR 0.92 versus 0.82 or 0.80, respectively), suggesting better tolerability of radiotherapy than other treatment modalities.
It is understandable that people with cardiopulmonary dysfunction are less actively treated because cardiopulmonary reserve is a critical consideration in decisions regarding the treatment of lung cancer. 4 However, people with communication impairment or brain/mental impairment do not have such a limitation, and any lack of treatment would stem from the difficulty of obtaining informed consent and/or the negative perception that people with a disability benefit less from active treatment. People with visual or hearing impairment often have limited access to health information and difficulty in communication for providing informed consent, 22 and people with brain/mental impairment have limited decision-making capacity. 23 Therefore, to optimize the treatment of these groups, it is necessary to develop decision aids to fit their special information and decision needs. 23 Overall mortality and lung cancer mortality showed a similar pattern, because most mortality occurs as a result of lung cancer (32,323 of 34,189 cases [94.5%]). Lung cancer mortality was slightly higher in patients with disabilities (aOR ¼ 1.08) and greater in severe cases (aOR ¼ 1.18), even after adjustment for the cancer stage and treatment received, suggesting some degree of contribution of disability itself to mortality. However, the magnitude of the difference was small and does not justify the less active treatment of this population. Furthermore, the lack of any obvious excess noncancer mortality also supports the need for equal treatment for people with disabilities if there is no contraindication. The reasons for higher mortality in the groups with brain/mental (aHR ¼ 1.37), physical (aHR ¼ 1.16), or communication (aHR ¼ 1.16) impairment after adjustment for the patient's medical condition and treatment needs to be investigated in further research. There are several possible explanations: (1) higher comorbidities or bad health behaviors that were not fully adjusted for in our study, 4, 24 (2) less intensive treatment (e.g., less extensive surgery and reduced dose of chemotherapy or radiotherapy), (3) less intensive supportive care, (4) poorer self-management or adherence to treatment, and (5) poor social support or living conditions. Optimization of treatment protocols for patients with disabilities, provision of supportive care and patient/caregiver education to meet the special needs of this population, and provision of social and economic support can be a strategy to reduce the disparity in treatment outcome.
Among those with cancer at a localized stage who underwent a surgical procedure, overall and lung cancer mortality was also higher in the group of those with a disability (aHR ¼ 1.28), and it was markedly so when the disability was severe (aHR ¼ 1.71). Among patients with different types of disability, people with physical disabilities showed significantly higher mortality (aHR ¼ 2.08), suggesting higher operative or postoperative risk owing to limited physical function, difficulties in postoperative self-management or rehabilitation, and/or less intensive adjuvant therapies. Patients with a brain/ mental disability also showed marginally higher mortality (aHR ¼ 1.54), suggesting the possibility of poor postoperative care owing to improper understanding of their disease and poor self-management skills and/or less intensive adjuvant therapies. On the other hand, people with a communication disability did not show disparity in treatment outcomes. Careful selection of surgical candidates, meticulous postoperative care (e.g., pulmonary rehabilitation and self-care), and optimization of adjuvant therapy are warranted to reduce the disparities in treatment outcomes.
Our study has several limitations. First, we did not know why some patients did not undergo diagnostic tests for staging or specific treatment (e.g. patient or family refusal, economic/transportation problem, or judgement by clinicians). Second, we did not have sufficient clinical information on preoperative function (e.g., pulmonary function test or 6-minute walking test results), the adequacy of treatment intensity (e.g., chemotherapy dose or number of radiation treatments), or adherence to postoperative care and self-management, which is important to interpret the disparity of treatment outcomes.
In conclusion, patients with lung cancer and disabilities, especially severe disabilities, underwent less staging work-up and treatment, although their treatment outcomes were only slightly worse than those of people without a disability. Although some degree of disparity might be attributed to reasonable clinical judgement, unequal clinical care for people with communication and brain/mental disabilities suggests unjustifiable, disabilityspecific barriers that need to be addressed. It seems necessary to educate health care professionals, as well as the people with disabilities and their families, to not have negative perceptions about the need for equal diagnosis and treatment. Further research is warranted to develop policies and guidelines to work toward equity in lung cancer diagnosis and treatment.
